Tag

Healthcare Diagnostics

11 articles
Thyrocare's strong Q2 FY27 results, marked by a 25.1% revenue increase and 25.7% profit growth, highlight the continued momentum within the Indian diagnostics sector. The divestment of its NHL subsidiary, while resulting in a one-time impairment charge, signals a strategic refocus on core franchise and institutional partnerships, alongside expansion into specialty diagnostics like allergy and genomics testing. With 61.6 million tests processed and the addition of new laboratories and franchisees, Thyrocare is reinforcing its operational capabilities and market reach, positioning the company for sustained growth despite potential headwinds from margin pressures and competitive dynamics. Investors should watch for the successful execution of the company’s growth strategy and its ability to maintain quality standards amidst expanding operations.
Suraksha Diagnostics Q2 PAT Up 69% YoY
Suraksha Diagnostic Limited reported unaudited Q2 FY27 standalone and consolidated financial results with PAT surging 69% YoY to ₹149.50 million. Total income grew 26% YoY to ₹1,005.75 million in Q2 F
Suraksha Diagnostic Q2 FY27 Net Profit Rises 63% YoY
Suraksha Diagnostic approved unaudited standalone and consolidated financial results for Q2 and H1 FY27, showing strong revenue and profit growth. Standalone Q2 revenue grew 24% YoY to ₹9,453 lakhs, w
Star Imaging H1 FY27 Investor Meet on Nov 18
Star Imaging schedules investor meet on November 18, 2026, to discuss H1 FY27 financial results. Management confirms no unpublished price-sensitive information will be shared during the earnings call.
Dr. Lal PathLabs Q2 FY27 Net Profit Up 27.5%
Dr. Lal PathLabs reported Q2 FY27 revenue of Rs. 874 crore, a 19.6% YoY growth, with patient volume increasing 9%. EBITDA grew 25.1% to Rs. 280 crore with a margin of 32.1%, while PAT increased 27.5%
Metropolis Healthcare Q2 FY27 Revenue Up 16%
Metropolis Healthcare reported strong Q2 FY27 results with revenue growth of 16% YoY and EBITDA margin expansion of 180 bps to 27.2%. The company declared an interim dividend of INR 1 per share and an
Krsnaa Diagnostics Q2 Revenue Hits ₹271 Crore
Krsnaa Diagnostics reported Q2 FY27 revenue of ₹271 crore, a 32% YoY growth, and H1 revenue crossed ₹500 crore for the first time. EBITDA margin moderated to 27% due to upfront costs from new Rajastha
Vijaya Diagnostic Q2 FY27 Revenue Up 26.7% YoY
Vijaya Diagnostic reported Q2 FY27 consolidated revenue of INR 255 crore, a 26.7% YoY growth driven by 16.5% volume growth and favorable test mix. EBITDA grew 37.8% YoY to INR 113 crore with a margin
Thyrocare Allots 194,289 ESOP Shares
Thyrocare Technologies allotted 194,289 equity shares under its Employee Stock Option Scheme via committee resolution. The allotment includes 129,526 shares from bonus adjustment, increasing paid-up c
Aspira Pathlab Q2 Net Loss of ₹1.16 Crore
Aspira Pathlab reported a standalone net loss of ₹1.16 crore for H1 FY27, with Q2 revenue declining to ₹6.35 crore. The company faces significant legal contingencies with three summary suits totaling
Thyrocare Promoter Docon Sells 9.9% Stake
Promoter Docon Technologies sold 1.58 crore Thyrocare shares representing 9.9% equity via market trades on August 13, 2026. Post-sale, promoter shareholding reduced from 60.92% to 51.02% of total paid
Thyrocare Promoter Releases Pledge on 17.5M Shares
Docon Technologies, Thyrocare's promoter, released pledge on 1.75 crore equity shares (10.99% stake) held as security for API Holdings' NCDs. The pledge release on August 11, 2026, reduces Docon's enc